FWBI
Income statement / Annual
Last year (2023), First Wave BioPharma, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, First Wave BioPharma, Inc.'s net income was -$15.79 M.
See First Wave BioPharma, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$29,274.00 |
$106,207.00 |
$537,400.00 |
$571,145.00 |
$976,982.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$29,274.00 |
-$106,207.00 |
-$537,400.00 |
-$571,145.00 |
-$976,982.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$5.03 M
|
$691,257.00
|
$38.32 M
|
$19.14 M
|
$8.68 M
|
$4.99 M
|
$2.40 M
|
$2.50 M
|
$1.40 M
|
| General & Administrative
Expenses |
$10.74 M
|
$11.99 M
|
$18.38 M
|
$7.29 M
|
$6.06 M
|
$8.24 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
-$29,274.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$10.71 M
|
$11.99 M
|
$18.38 M
|
$7.29 M
|
$6.06 M
|
$8.24 M
|
$7.69 M
|
$4.13 M
|
$3.33 M
|
| Other Expenses |
$0.00 |
-$232,741.00 |
$529,101.00 |
$211,430.00 |
$0.00 |
-$210,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$15.74 M |
$12.68 M |
$56.70 M |
$26.43 M |
$14.74 M |
$13.43 M |
$10.08 M |
$6.63 M |
$4.73 M |
| Cost And Expenses |
$15.77 M |
$12.68 M |
$56.70 M |
$26.43 M |
$14.74 M |
$13.43 M |
$10.08 M |
$6.63 M |
$4.73 M |
| Interest Income |
$19,932.00 |
$8,415.00 |
$1,173.00 |
$484.00 |
$433.94 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$15,879.00 |
$11,235.00 |
$5.84 M |
$433,939.00 |
$101,846.00 |
$875,199.00 |
$5.94 M |
$1.59 M |
| Depreciation &
Amortization |
$29,274.00
|
-$195,055.00
|
$3.42 M
|
$777,259.00
|
$1.02 M
|
$798,446.00
|
$753,998.00
|
$734,500.00
|
$733,599.00
|
| EBITDA |
-$15.74 M
|
-$12.87 M
|
-$55.63 M
|
-$25.66 M
|
-$13.72 M
|
-$12.63 M
|
-$9.33 M
|
-$5.89 M
|
-$4.00 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$24,153.00
|
-$1.95 M
|
-$1.83 M
|
-$6.24 M
|
-$433,939.00
|
-$311,846.00
|
-$875,199.00
|
-$8.27 M
|
-$1.20 M
|
| Income Before Tax |
-$15.79 M |
-$14.63 M |
-$58.54 M |
-$32.67 M |
-$15.18 M |
-$13.53 M |
-$11.10 M |
-$14.59 M |
-$5.93 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$4.00 |
$1.95 M |
$540,336.00 |
$6.05 M |
$433,939.00 |
-$108,154.00 |
$875,199.00 |
$5.94 M |
$1.59 M |
| Net Income |
-$15.79 M |
-$16.58 M |
-$59.08 M |
-$38.72 M |
-$15.61 M |
-$13.53 M |
-$11.10 M |
-$14.59 M |
-$5.93 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-46.96 |
-461.72 |
-27799.23 |
-57194.08 |
-29238.43 |
-1840.81 |
-2192.53 |
-4711.55 |
-1293.12 |
| EPS Diluted |
-46.96 |
-461.72 |
-27799.23 |
-57194.08 |
-29238.43 |
-1840.81 |
-2192.53 |
-4711.55 |
-1261.75 |
| Weighted Average Shares
Out |
$336,342.00
|
$35,912.00
|
$2,125.17
|
$677.05
|
$533.94
|
$7,352.00
|
$5,061.00
|
$3,097.00
|
$4,586.00
|
| Weighted Average Shares
Out Diluted |
$336,342.00
|
$35,912.00
|
$2,125.17
|
$677.05
|
$533.94
|
$7,352.00
|
$5,061.00
|
$3,097.00
|
$4,700.00
|
| Link |
|
|
|
|
|
|
|
|
|
